Zai Lab Presents Preclinical Data on ZL-1503 Targeting IL-13 and IL-31Rα for Itch Relief and Inflammation Reduction in Atopic Diseases

Zai Lab has unveiled preclinical data indicating that its investigational bispecific antibody, ZL-1503, may offer rapid itch relief and reduce inflammation in atopic diseases. The findings, presented on April 18, 2026, highlight the potential of ZL-1503 to target both IL-13 and IL-31Rα pathways, which are associated with inflammatory and pruritic responses in conditions such as atopic dermatitis.

The research demonstrated that ZL-1503 effectively inhibited signaling through these pathways in preclinical models. This dual mechanism of action reportedly led to a significant reduction in itch-related behaviors and markers of inflammation. These results suggest that ZL-1503 could address key symptoms of atopic diseases by simultaneously targeting two critical drivers of disease pathology. Further studies will be needed to confirm these findings and evaluate the safety and efficacy of ZL-1503 in clinical settings.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 18, 2026

Author

GOAI